About 200000 cardiac operations are performed in China every year. Cardiopulmonary bypass is the basic strategy of open-heart surgery, which may lead to myocardial ischemia-reperfusion injury and low cardiac output syndrome. It will inevitably affect the patient's postoperative recovery. A number of studies have shown that dexmedetomidine, as an auxiliary sedative, has the effects of inhibiting stress response, antiarrhythmia and cardiac protection.Dexmedetomidine has been widely used in anesthesia in cardiac surgery. However, at present, few clinical studies pay attention to its mechanism. In this study, dexmedetomidine will be used in cardiac surgery with cardiopulmonary bypass to explore the mechanism of cardiac ischemia-reperfusion injury and the protective effect of dexmedetomidine.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
64
The participant will pump dexmedetomidine at the rate of 1μg/(Kg·h) for 10 minutes at the beginning of anesthesia induction, and then maintain the pump at a rate of 0.5μg/(Kg·h) during the operation.
The participant will pump saline without dexmedetomidine at the same speed as group D.
Affiliated Hospital Nantong University
Nantong, Jiangsu, China
troponin T level
the level of troponin in the participant's serum
Time frame: before operation
troponin T level
the level of troponin in the participant's serum
Time frame: the end of operation
troponin T level
the level of troponin in the participant's serum
Time frame: when the participant returned to the ward after the operation
troponin T level
the level of troponin in the participant's serum
Time frame: 24 hours after operation
troponin T level
the level of troponin in the participant's serum
Time frame: 72 hours after operation
AQP4、iNOS andTNF-α level
the level of AQP4、iNOS andTNF-α in the participant's serum
Time frame: before operation
AQP4、iNOS andTNF-α level
the level of AQP4、iNOS andTNF-α in the participant's serum
Time frame: when blocking the ascending aorta
AQP4、iNOS andTNF-α level
the level of AQP4、iNOS andTNF-α in the participant's serum
Time frame: when developing the ascending aorta
AQP4、iNOS andTNF-α level
the level of AQP4、iNOS andTNF-α in the participant's serum
Time frame: when cardiopulmonary bypass is stopped
AQP4、iNOS andTNF-α level
the level of AQP4、iNOS andTNF-α in the participant's serum
Time frame: the end of the operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.